Novavax Inc.

Sinnathurai v. Novavax, Inc. et al., (Case No. 8:21cv02910), D. Md.

On October 19, 2021, after the market closed, Politico published an article, titled “’They Rushed the Process’: Vaccine Maker’s woes hamper global inoculation campaign”, alleging manufacturing and purity problems in Novavax’s process to produce Covid-19 vaccinations for COVAX, an international consortium working to provide two billion doses to middle and low income countries. Previously, the U.S. government invested $1.6B in Novavax in 2020, the most devoted to any vaccine manufacturer at the time.

On this news shares of Novavax fell over 20% in premarket trading on October 20, 2021.

Lead Plaintiff deadline
January 11, 2022
class period
March 2, 2021
October 19, 2021
Case Documents
No documents available. Contact us if you need a case document.